---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-004875"
form_type: "8-K"
ticker: "RTGN"
cik: "0001836295"
company_name: "RetinalGenix Technologies Inc."
filed_at: "2022-02-17T23:59:59+00:00"
generated_at: "2026-06-27T07:08:55.473610+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# RetinalGenix and Diopsys terminate 2019 Option Exchange Agreement; no options ever issued

## Summary
- Termination effective Feb 14, 2022; Agreement from Oct 8, 2019 never had conditions satisfied.
- No options were issued under the agreement, and the contemplated Exclusive Distribution Agreement was never negotiated.
- Both parties are mutually released from any claims related to the Agreement and its termination.
- RetinalGenix and Diopsys continue discussions toward a potential Exclusive Distribution Agreement.

## SEC filing metadata
- accession: 0001493152-22-004875
- form_type: 8-K
- ticker: RTGN
- cik: 0001836295
- company_name: RetinalGenix Technologies Inc.
- filed_at: 2022-02-17T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1836295/000149315222004875/0001493152-22-004875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1836295/000149315222004875/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-004875
- JSON: https://secwatch.observer/filing/0001493152-22-004875.json
- Plain text: https://secwatch.observer/filing/0001493152-22-004875.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.